Physician profile
Mark Dawkins
NPI 1114909405
$56,230.70
in general payments reported to CMS, 2019-2025
40 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $1,568 · 2021: $2,436 · 2022: $9,156 · 2023: $13K · 2024: $16K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $10K · Travel and Lodging: $860 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,202.50 |
| Food and Beverage | $10,052.60 |
| Travel and Lodging | $859.67 |
| Education | $223.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $40,007.38 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,701.85 | 2019-2025 | |
| Lilly USA, LLC | $1,623.14 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $1,547.97 | 2019-2025 | |
| Ucb, INC. | $1,517.50 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,202.10 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $1,115.77 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $1,071.97 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $963.19 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $887.23 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| Amgen INC. | $853.78 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $506.77 | 2019-2025 | |
| Galderma Laboratories, L.P. | $479.64 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $458.00 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $440.35 | 2023-2025 | Zoryve |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.